Peptides Similar to Cebranopadol
Compare Cebranopadol with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Ziconotide: Both are non-traditional analgesics with novel mechanisms that differ from conventional opioids. Both target pain pathways without acting solely through the mu-opioid receptor.
- •Dermorphin: Both interact with opioid receptors to produce analgesia. Dermorphin is an endogenous mu-opioid receptor agonist peptide, while cebranopadol is a synthetic dual NOP/MOP agonist.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Cebranopadol (current) | - | - |
| Ziconotide | Both are non-traditional analgesics with novel mechanisms that differ from conventional opioids. Both target pain pathways without acting solely through the mu-opioid receptor. | Ziconotide blocks N-type calcium channels (Cav2.2) in the spinal cord and requires intrathecal administration. Cebranopadol acts on NOP/opioid receptors and is taken orally. Ziconotide is FDA-approved; cebranopadol is investigational. |
| Dermorphin | Both interact with opioid receptors to produce analgesia. Dermorphin is an endogenous mu-opioid receptor agonist peptide, while cebranopadol is a synthetic dual NOP/MOP agonist. | Dermorphin is a naturally occurring peptide requiring injection with a short half-life. Cebranopadol is a small molecule taken orally with a 62-96 hour half-life. Dermorphin acts only on mu-opioid receptors; cebranopadol also activates NOP receptors. |
ZiconotideBoth are non-traditional analgesics with novel mechanisms that differ from conventional opioids. Both target pain pathways without acting solely through the mu-opioid receptor.
Differences
Ziconotide blocks N-type calcium channels (Cav2.2) in the spinal cord and requires intrathecal administration. Cebranopadol acts on NOP/opioid receptors and is taken orally. Ziconotide is FDA-approved; cebranopadol is investigational.
Advantages
Oral administration (no intrathecal pump needed). Broader applicability to multiple pain types. Favorable abuse liability profile demonstrated in clinical studies.
Disadvantages
Retains opioid receptor activity with associated side effects at higher doses. Investigational status (not yet approved). Less established long-term safety data.
DermorphinBoth interact with opioid receptors to produce analgesia. Dermorphin is an endogenous mu-opioid receptor agonist peptide, while cebranopadol is a synthetic dual NOP/MOP agonist.
Differences
Dermorphin is a naturally occurring peptide requiring injection with a short half-life. Cebranopadol is a small molecule taken orally with a 62-96 hour half-life. Dermorphin acts only on mu-opioid receptors; cebranopadol also activates NOP receptors.
Advantages
Oral bioavailability. Much longer half-life enabling once-daily dosing. Additional NOP receptor activity reduces abuse potential and respiratory depression risk.
Disadvantages
Synthetic small molecule rather than natural peptide. More complex side effect profile. Investigational status.
Peptides and Agents Related to Cebranopadol#
Cebranopadol occupies a unique pharmacological position as the first dual NOP/opioid receptor agonist in late-stage clinical development. The most relevant comparisons span peptide-based analgesics, traditional opioids, and dual-mechanism analgesics.
Ziconotide (Prialt)#
Ziconotide is an FDA-approved synthetic peptide analgesic derived from the omega-conotoxin MVIIA of the cone snail Conus magus. It blocks N-type voltage-gated calcium channels (Cav2.2) in the spinal cord, inhibiting pain-signaling neurotransmitter release.
Mechanism comparison: Ziconotide targets calcium channels in the spinal cord via intrathecal delivery, while cebranopadol modulates NOP/opioid receptor signaling systemically via oral administration. Neither relies solely on the mu-opioid receptor, but their non-opioid mechanisms are entirely different.
Clinical positioning: Ziconotide is reserved for severe chronic pain refractory to other treatments, requiring an implanted intrathecal pump. Cebranopadol is being developed as a first-line to second-line oral analgesic for a broader population.
| Parameter | Cebranopadol | Ziconotide |
|---|---|---|
| Class | NOP/opioid receptor agonist | N-type calcium channel blocker |
| Route | Oral (once daily) | Intrathecal (continuous infusion) |
| Primary target | NOP + MOP receptors | Cav2.2 channels |
| Abuse potential | Low (vs opioids) | None |
| Regulatory status | Phase 3 (NDA planned) | FDA-approved (2004) |
| Indication breadth | Acute and chronic pain | Severe chronic pain only |
| Key AEs | Nausea, dizziness, somnolence | CNS effects, psychiatric symptoms |
Dermorphin#
Dermorphin is a naturally occurring heptapeptide originally isolated from frog skin that acts as a highly selective mu-opioid receptor agonist with potency approximately 30-40 times that of morphine.
Mechanism comparison: Dermorphin is a pure MOP agonist peptide, while cebranopadol adds NOP receptor activity to its opioid effects. This dual mechanism gives cebranopadol reduced abuse potential and respiratory depression risk that pure MOP agonists like dermorphin lack.
Clinical relevance: Dermorphin serves primarily as a research tool and pharmacological reference rather than a clinical therapeutic, while cebranopadol is in active clinical development.
Tapentadol (Nucynta)#
Tapentadol is an FDA-approved oral analgesic with a dual mechanism combining MOP receptor agonism with norepinephrine reuptake inhibition (NRI). It was included as an active comparator in cebranopadol's Phase 2 chronic LBP trial.
Mechanism comparison: Both provide analgesia beyond pure mu-opioid agonism, but through different complementary mechanisms. Tapentadol's NRI component enhances descending inhibitory pain pathways, while cebranopadol's NOP component modulates the nociceptin/orphanin FQ system.
Clinical data: In the Phase 2 chronic LBP trial, tapentadol 200 mg twice daily and cebranopadol showed comparable efficacy, both significantly superior to placebo.
Traditional Opioids (Morphine, Oxycodone)#
Traditional opioids act primarily through MOP receptor agonism without the NOP component that distinguishes cebranopadol.
| Feature | Cebranopadol | Oxycodone | Morphine |
|---|---|---|---|
| Mechanism | NOP + MOP agonist | Pure MOP agonist | Pure MOP agonist |
| Route | Oral once daily | Oral Q4-6H (IR) | Oral Q4H / IV |
| Abuse potential | Low (at clinical doses) | High (Schedule II) | High (Schedule II) |
| Respiratory depression | Reduced risk | Significant risk | Significant risk |
| Regulatory | Investigational | Approved | Approved |
In the ALLEVIATE-2 Phase 3 trial, cebranopadol 400 mcg once daily showed comparable or superior efficacy to oxycodone IR 10 mg four times daily, with a more favorable safety profile.
Summary Comparison#
| Feature | Cebranopadol | Ziconotide | Tapentadol | Morphine |
|---|---|---|---|---|
| Mechanism | NOP + MOP | Ca2+ channel block | MOP + NRI | Pure MOP |
| Route | Oral QD | Intrathecal | Oral BID | Oral/IV Q4H |
| Abuse potential | Low | None | Moderate | High |
| Approved | No (Phase 3) | Yes (2004) | Yes (2008) | Yes |
| Pain types | Acute + chronic | Severe chronic | Moderate-severe | All types |
Related Reading#
Frequently Asked Questions About Cebranopadol
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer